Repare Therapeutics Inc.
DelistedCIK 1808158fmd_1X2QXYA299QXQ9YMF58PF9X6SMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2025, 26 periods
Latest annual · FY2024
Millions- Operating income
- (94)
- Net income
- (85)
- Free cash flow
- (76)
Latest quarter · Q3 FY2025
Millions- Operating income
- 1
- Net income
- 3
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2019 to FY2024
- n/m
Repare Therapeutics Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$93.5 million | -$116.2 million | 10-K 2025-03-03 · proof | |
| Net income | -$84.7 million | -$93.8 million | 10-K 2025-03-03 · proof | |
| Cash from operating activities | -$76.4 million | -$127.2 million | 10-K 2025-03-03 · proof | |
| Free cash flow | -$76.4 million | -$129.1 million | 10-K 2025-03-03 · proof | |
| Total assets | $176.5 million | $253.9 million | -30.5% | 10-K 2025-03-03 · proof |
| Total liabilities | $25.4 million | $41.8 million | -39.3% | 10-K 2025-03-03 · proof |
| Cash and cash equivalents | $84.7 million | $111.3 million | -23.9% | 10-K 2025-03-03 · proof |
- What was Repare Therapeutics Inc.'s operating income in fiscal 2024?
- Repare Therapeutics Inc. reported operating income of -$93.5 million for fiscal 2024 (the year ended Dec 31, 2024), against -$116.2 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What was Repare Therapeutics Inc.'s net income in fiscal 2024?
- Repare Therapeutics Inc. reported net income of -$84.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$93.8 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What was Repare Therapeutics Inc.'s cash from operating activities in fiscal 2024?
- Repare Therapeutics Inc. reported cash from operating activities of -$76.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$127.2 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What was Repare Therapeutics Inc.'s free cash flow in fiscal 2024?
- Repare Therapeutics Inc. reported free cash flow of -$76.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$129.1 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What are Repare Therapeutics Inc.'s total assets?
- As of Dec 31, 2024, Repare Therapeutics Inc. reported total assets of $176.5 million, against $253.9 million a year earlier (-30.5%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What are Repare Therapeutics Inc.'s total liabilities?
- As of Dec 31, 2024, Repare Therapeutics Inc. reported total liabilities of $25.4 million, against $41.8 million a year earlier (-39.3%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What are Repare Therapeutics Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Repare Therapeutics Inc. reported cash and cash equivalents of $84.7 million, against $111.3 million a year earlier (-23.9%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1808158&period_type=annual&limit=5"Information only, not investment advice.